{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T04:26:28Z","timestamp":1762057588329,"version":"build-2065373602"},"reference-count":179,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T00:00:00Z","timestamp":1655942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hemato"],"abstract":"<jats:p>The introduction of new and more effective therapeutic options for Multiple Myeloma (MM) has significantly deepened and prolonged patients\u2019 remission. As currently used treatment protocols induce high rates of complete responses, Measurable Residual Disease (MRD) assessment has become essential to enhance the evaluation of treatment efficacy. Detection of MRD has improved with the development of highly sensitive and standardized techniques such as Next Generation Flow or Next Generation Sequencing, complemented by functional imaging techniques. These advances offer a valuable opportunity to further optimize criteria of response to treatment. Currently, extensive data demonstrate that MRD status is a valuable prognostic factor of survival. Since MRD represents a real measurement of disease burden, its incorporation in clinical trials to guide treatment decisions will certainly translate into clinical benefits. Sustained MRD negativity can be used to consider optimal candidates for treatment discontinuation, whereas MRD positive high-risk patients may have access to novel immunotherapeutic strategies such as bispecific drugs or CAR T cell therapy. In this review, we describe the available techniques to detect MRD, address the current data regarding MRD as a surrogate endpoint within clinical trials, examine how MRD can be introduced into the clinical management of MM patients, and discuss the future of MRD monitoring.<\/jats:p>","DOI":"10.3390\/hemato3030027","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T21:25:00Z","timestamp":1656019500000},"page":"385-413","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Measurable Residual Disease Assessment in Multiple Myeloma: How Deep Is Enough?"],"prefix":"10.3390","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7509-9066","authenticated-orcid":false,"given":"Joana","family":"Caetano","sequence":"first","affiliation":[{"name":"Hemato-Oncology Unit, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"Myeloma Lymphoma Research Group, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"NOVA Medical School, Universidade Nova de Lisboa, 1169-056 Lisbon, Portugal"}]},{"given":"Filipa","family":"Barahona","sequence":"additional","affiliation":[{"name":"Myeloma Lymphoma Research Group, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"NOVA Medical School, Universidade Nova de Lisboa, 1169-056 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0175-7534","authenticated-orcid":false,"given":"Paulo","family":"L\u00facio","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Unit, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"Myeloma Lymphoma Research Group, Champalimaud Foundation, 1400-038 Lisbon, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3978-766X","authenticated-orcid":false,"given":"Cristina","family":"Jo\u00e3o","sequence":"additional","affiliation":[{"name":"Hemato-Oncology Unit, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"Myeloma Lymphoma Research Group, Champalimaud Foundation, 1400-038 Lisbon, Portugal"},{"name":"NOVA Medical School, Universidade Nova de Lisboa, 1169-056 Lisbon, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2022,6,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","article-title":"Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: Updated analysis of CASTOR","volume":"103","author":"Spencer","year":"2018","journal-title":"Haematologica"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","article-title":"Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial","volume":"395","author":"Mateos","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1182\/blood.2020005288","article-title":"Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial","volume":"136","author":"Voorhees","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study","volume":"394","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1182\/blood-2010-09-307645","article-title":"Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: Analysis of 1175 patients","volume":"117","author":"Gay","year":"2011","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5775","DOI":"10.1200\/JCO.2008.17.9721","article-title":"Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival","volume":"26","author":"Lahuerta","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Ortiz, A., Rodr\u00edguez-Garc\u00eda, Y., Encinas, J., Maroto-Mart\u00edn, E., Castellano, E., Teixid\u00f3, J., and Mart\u00ednez-L\u00f3pez, J. (2021). The Role of Tumor Microenvironment in Multiple Myeloma Development and Progression. Cancers, 13.","DOI":"10.3390\/cancers13020217"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Lopes, R., Caetano, J., Ferreira, B., Barahona, F., Carneiro, E.A., and Jo\u00e3o, C. (2021). The Immune Microenvironment in Multiple Myeloma: Friend or Foe?. Cancers, 13.","DOI":"10.3390\/cancers13040625"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e752","DOI":"10.1016\/j.clml.2020.05.026","article-title":"Role of the Bone Marrow Milieu in Multiple Myeloma Progression and Therapeutic Resistance","volume":"20","author":"Ho","year":"2020","journal-title":"Clin. Lymphoma. Myeloma Leuk."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1182\/blood.V99.5.1853","article-title":"Immunophenotypic evaluation of the plasma cell compartment in multiple myeloma: A tool for comparing the efficacy of different treatment strategies and predicting outcome","volume":"99","author":"Almeida","year":"2002","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4017","DOI":"10.1182\/blood-2008-05-159624","article-title":"Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation","volume":"112","author":"Paiva","year":"2008","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2001-12-0297","article-title":"Flow cytometric disease monitoring in multiple myeloma: The relationship between normal and neoplastic plasma cells predicts outcome after transplantation","volume":"100","author":"Rawstron","year":"2002","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1182\/blood.V126.23.191.191","article-title":"Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM\/DFCI 2009 Trial","volume":"126","author":"Corre","year":"2015","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1038\/leu.2017.29","article-title":"Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma","volume":"31","author":"Paiva","year":"2017","journal-title":"Leukemia"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/cyto.b.21249","article-title":"Consensus guidelines for myeloma minimal residual disease sample staining and data acquisition","volume":"90","author":"Paiva","year":"2016","journal-title":"Cytom. Part B-Clin. Cytom."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/leu.2010.160","article-title":"Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: A step forward in the standardization of clinical immunophenotyping","volume":"24","author":"Costa","year":"2010","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1182\/bloodadvances.2016003715","article-title":"MRD detection in multiple myeloma: Comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods","volume":"1","author":"Roshal","year":"2017","journal-title":"Blood Adv."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1182\/blood-2019-130607","article-title":"Comparison of the Performance of Surface Alone or Surface Plus Cytoplasmic Approaches for the Assessment of Minimal Residual Disease in Multiparameter Flow Cytometry in Multiple Myeloma","volume":"134","author":"Bene","year":"2019","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.3324\/haematol.2019.238394","article-title":"Validated single-tube multiparameter flow cytometry approach for the assessment of minimal residual disease in multiple myeloma","volume":"105","author":"Dold","year":"2020","journal-title":"Haematologica"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/leu.2012.120","article-title":"EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes","volume":"26","author":"Lhermitte","year":"2012","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1038\/leu.2014.321","article-title":"Phenotypic identification of subclones in multiple myeloma with different chemoresistant, cytogenetic and clonogenic potential","volume":"29","author":"Paiva","year":"2015","journal-title":"Leukemia"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zannetti, B.A., Faini, A.C., Massari, E., Geuna, M., Maffini, E., Poletti, G., Cerchione, C., Martinelli, G., Malavasi, F., and Lanza, F. (2020). Novel Insights in Anti-CD38 Therapy Based on CD38-Receptor Expression and Function: The Multiple Myeloma Model. Cells, 9.","DOI":"10.3390\/cells9122666"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41375-020-01012-4","article-title":"International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials","volume":"35","author":"Costa","year":"2021","journal-title":"Leukemia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","article-title":"Measurable residual disease by next-generation flow cytometry in multiple myeloma","volume":"38","author":"Paiva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-021-00498-0","article-title":"Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02\/HOVON 95 MM trial","volume":"11","author":"Oliva","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1182\/blood-2014-07-590166","article-title":"Minimal residual disease in myeloma by flow cytometry: Independent prediction of survival benefit per log reduction","volume":"125","author":"Rawstron","year":"2015","journal-title":"Blood"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomised, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1182\/blood.2020007522","article-title":"Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma","volume":"136","author":"Jasielec","year":"2020","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1200\/EDBK_159088","article-title":"Minimal Residual Disease by Next-Generation Sequencing: Pros and Cons","volume":"36","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book."},{"key":"ref_32","first-page":"951","article-title":"Monitoring multiple myeloma","volume":"15","author":"Udd","year":"2017","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"699","DOI":"10.3389\/fonc.2019.00699","article-title":"Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives","volume":"9","author":"Gozzetti","year":"2019","journal-title":"Front. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood-2011-01-332320","article-title":"Long-term prognostic significance of response in multiple myeloma after stem cell transplantation","volume":"118","author":"Blade","year":"2011","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1182\/blood-2009-06-230250","article-title":"Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: A European MCL intergroup study","volume":"115","author":"Pott","year":"2010","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15075","article-title":"Molecular detection of minimal residual disease in multiple myeloma","volume":"181","author":"Bai","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Lahuerta","year":"2014","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","article-title":"Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma","volume":"132","author":"Perrot","year":"2018","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1093\/annonc\/mdx340","article-title":"Prognostic value of sequencing-based minimal residual disease detection in patients with multiple myeloma who underwent autologous stem-cell transplantation","volume":"28","author":"Takamatsu","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","article-title":"Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma","volume":"378","author":"Mateos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1002\/acg2.26","article-title":"Meeting report: Advances in minimal residual disease testing in multiple myeloma 2018","volume":"2","author":"Landgren","year":"2019","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Takamatsu, H. (2017). Comparison of minimal residual disease detection by multiparameter flow cytometry, ASO-qPCR, droplet digital PCR, and deep sequencing in patients with multiple myeloma who underwent autologous stem cell transplantation. J. Clin. Med., 6.","DOI":"10.3390\/jcm6100091"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1158\/1078-0432.CCR-14-2841","article-title":"Is this the time to introduce minimal residual disease in multiple myeloma clinical practice?","volume":"21","author":"Paiva","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s11899-014-0237-y","article-title":"Controversies in the Assessment of Minimal Residual Disease in Multiple Myeloma: Clinical Significance of Minimal Residual Disease Negativity Using Highly Sensitive Techniques","volume":"9","author":"Biran","year":"2014","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1038\/nbt.2403","article-title":"Assuring the quality of next-generation sequencing in clinical laboratory practice","volume":"30","author":"Gargis","year":"2012","journal-title":"Nat. Biotechnol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1038\/s41375-019-0496-7","article-title":"Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study","volume":"33","author":"Knecht","year":"2019","journal-title":"Leukemia"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"8533","DOI":"10.1200\/JCO.2020.38.15_suppl.8533","article-title":"Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM)","volume":"38","author":"Oliva","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2017.58","article-title":"Analytical and clinical validation of a novel in-house deep-sequencing method for minimal residual disease monitoring in a phase II trial for multiple myeloma","volume":"31","author":"Barrio","year":"2017","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1016\/j.clml.2019.09.005","article-title":"Concordance of Post-consolidation Minimal Residual Disease Rates by Multiparametric Flow Cytometry and Next-generation Sequencing in CASSIOPEIA","volume":"19","author":"Bene","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"e530","DOI":"10.1038\/bcj.2017.14","article-title":"Discrepancies between the percentage of plasma cells in bone marrow aspiration and BM biopsy: Impact on the revised IMWG diagnostic criteria of multiple myeloma","volume":"7","author":"Lee","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3109\/10428194.2012.740559","article-title":"Challenges and opportunities of novel imaging techniques in monoclonal plasma cell disorders: Imaging \u201cearly myeloma\u201d","volume":"54","author":"Hillengass","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1097\/RLU.0b013e31825b2071","article-title":"FDG PET or PET\/CT for detecting intramedullary and extramedullary lesions in multiple Myeloma: A systematic review and meta-analysis","volume":"37","author":"Lu","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e302","DOI":"10.1016\/S1470-2045(19)30309-2","article-title":"International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders","volume":"20","author":"Hillengass","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1016\/S1470-2045(17)30189-4","article-title":"Role of 18F-FDG PET\/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: A consensus statement by the International Myeloma Working Group","volume":"18","author":"Cavo","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"5984","DOI":"10.1182\/blood-2011-09-379818","article-title":"PET-CT in MM: A new definition of CR","volume":"118","author":"Moreau","year":"2011","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.2011.34.9290","article-title":"Soft-tissue plasmacytomas in multiple myeloma: Incidence, mechanisms of extramedullary spread, and treatment approach","volume":"29","author":"Cibeira","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3324\/haematol.10554","article-title":"A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma","volume":"92","author":"Zamagni","year":"2007","journal-title":"Haematologica"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2017.72.2975","article-title":"Prospective Evaluation of Magnetic Resonance Imaging and [(18)F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM\/DFCI 2009 Trial: Results of the IMAJEM Study","volume":"35","author":"Moreau","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4384","DOI":"10.1158\/1078-0432.CCR-15-0396","article-title":"PET\/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma","volume":"21","author":"Zamagni","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/bjh.12007","article-title":"The role of imaging techniques in the management of multiple myeloma","volume":"159","author":"Zamagni","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_65","first-page":"479","article-title":"Application of (18)F-FDG PET and diffusion weighted imaging (DWI) in multiple myeloma: Comparison of functional imaging modalities","volume":"5","author":"Sachpekidis","year":"2015","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/leu.2015.338","article-title":"Whole-body diffusion-weighted MRI: A new gold standard for assessing disease burden in patients with multiple myeloma?","volume":"30","author":"Pawlyn","year":"2016","journal-title":"Leukemia"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Morales-Lozano, M.I., Viering, O., Samnick, S., Rodriguez-Otero, P., Buck, A.K., Marcos-Jubilar, M., Rasche, L., Prieto, E., Kort\u00fcm, K.M., and San-Miguel, J. (2020). 18F-FDG and 11C-Methionine PET\/CT in Newly Diagnosed Multiple Myeloma Patients: Comparison of Volume-Based PET Biomarkers. Cancers, 12.","DOI":"10.3390\/cancers12041042"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative FDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1053\/j.seminhematol.2018.02.009","article-title":"Functional Imaging Methods for Assessment of Minimal Residual Disease in Multiple Myeloma: Current Status and Novel ImmunoPET Based Methods","volume":"55","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET of Multiple Myeloma: From Xenograft Models to First-in-Human Imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1182\/blood-2019-123143","article-title":"Evaluation of the Prognostic Value of Positron Emission Tomography-Computed Tomography (PET-CT) at Diagnosis and Follow-up in Transplant-Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients Treated in the Phase 3 Cassiopeia Study: Results of the Cassiopet Companion Study","volume":"134","author":"Moreau","year":"2019","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1038\/s41375-018-0329-0","article-title":"Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma","volume":"33","author":"Rasche","year":"2019","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-06-361386","article-title":"Prognostic relevance of 18-F FDG PET\/CT in newly diagnosed multiple myeloma patients treated with up-front autologous transplantation","volume":"118","author":"Zamagni","year":"2011","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2021-150937","article-title":"The Spatial Heterogeneity in Newly Diagnosed Multiple Myeloma Patients\u2014From Sub-Clonal Architecture to the Immune Microenvironment","volume":"138","author":"John","year":"2021","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/978-1-4939-9004-7_17","article-title":"Single-Cell Analysis of Circulating Tumor Cells","volume":"1908","author":"Thiele","year":"2019","journal-title":"Methods Mol. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.celrep.2017.03.025","article-title":"The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma","volume":"19","author":"Mishima","year":"2017","journal-title":"Cell Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"363ra147","DOI":"10.1126\/scitranslmed.aac7037","article-title":"Genetic interrogation of circulating multiple myeloma cells at single-cell resolution","volume":"8","author":"Lohr","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1038\/s41467-018-04001-5","article-title":"Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma","volume":"9","author":"Manier","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1046\/j.1365-2141.1997.72653.x","article-title":"Circulating plasma cells in multiple myeloma: Characterization and correlation with disease stage","volume":"97","author":"Rawstron","year":"1997","journal-title":"Br. J. Haematol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2005-05-1858","article-title":"Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma","volume":"106","author":"Nowakowski","year":"2005","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/leu.2014.98","article-title":"Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: Implications for redefining high-risk myeloma","volume":"28","author":"Gonsalves","year":"2014","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/bjh.13067","article-title":"Quantification of clonal circulating plasma cells in relapsed multiple myeloma","volume":"167","author":"Gonsalves","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e512","DOI":"10.1038\/bcj.2016.117","article-title":"Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era","volume":"6","author":"Chakraborty","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5668","DOI":"10.1200\/JCO.2005.03.159","article-title":"Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance","volume":"23","author":"Kumar","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/leu.2016.205","article-title":"Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression","volume":"31","author":"Gonsalves","year":"2017","journal-title":"Leukemia"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/ajh.25709","article-title":"Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells","volume":"95","author":"Gonsalves","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1080\/16078454.2021.1948208","article-title":"Prognostic value of circulating clonal plasma cells in newly diagnosed multiple myeloma","volume":"26","author":"Han","year":"2021","journal-title":"Hematology"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/s41408-018-0153-9","article-title":"Next generation flow for minimally-invasive blood characterization of MGUS and multiple myeloma at diagnosis based on circulating tumor plasma cells (CTPC)","volume":"8","author":"Paiva","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"4338","DOI":"10.1182\/blood-2019-127989","article-title":"Next Generation Flow Cytometry Provides a Standardized, Highly Sensitive and Informative Method for the Analysis of Circulating Plasma Cells in Newly Diagnosed Multiple Myeloma: A Single Center Study in 182 Patients","volume":"134","author":"Terpos","year":"2019","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1182\/blood.2019002610","article-title":"Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy","volume":"134","author":"Puig","year":"2019","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"3591","DOI":"10.1182\/blood-2013-06-510453","article-title":"Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile","volume":"122","author":"Paiva","year":"2013","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1182\/bloodadvances.2018025197","article-title":"Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow","volume":"2","author":"Mazzotti","year":"2018","journal-title":"Blood Adv."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/bmt.2017.91","article-title":"Circulating tumor cells as a biomarker for response to therapy in multiple myeloma patients treated within the GMMG-MM5 trial","volume":"52","author":"Huhn","year":"2017","journal-title":"Bone Marrow Transplant."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1038\/s41375-020-0883-0","article-title":"Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma","volume":"34","author":"Bretones","year":"2020","journal-title":"Leukemia"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Mathai, R.A., Vidya, R.V.S., Reddy, B.S., Thomas, L., Udupa, K., Kolesar, J., and Rao, M. (2019). Potential Utility of Liquid Biopsy as a Diagnostic and Prognostic Tool for the Assessment of Solid Tumors: Implications in the Precision Oncology. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030373"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.jmoldx.2018.07.006","article-title":"Noninvasive Molecular Monitoring in Multiple Myeloma Patients Using Cell-Free Tumor DNA: A Pilot Study","volume":"20","author":"Biancon","year":"2018","journal-title":"J. Mol. Diagn."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"15086","DOI":"10.1038\/ncomms15086","article-title":"Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates","volume":"8","author":"Kis","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.3324\/haematol.2016.161414","article-title":"Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA","volume":"102","author":"Oberle","year":"2017","journal-title":"Haematologica"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/ejh.13358","article-title":"Dynamics of tumor-specific cfDNA in response to therapy in multiple myeloma patients","volume":"104","author":"Vrabel","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/hemato3010006","article-title":"Is Circulating DNA and Tumor Cells in Myeloma the Way Forward?","volume":"3","author":"Barahona","year":"2022","journal-title":"Hemato"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/j.seminhematol.2018.02.008","article-title":"Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease","volume":"55","author":"Thoren","year":"2018","journal-title":"Semin. Hematol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"e590","DOI":"10.1038\/bcj.2017.75","article-title":"High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma","volume":"7","author":"Mills","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1373\/clinchem.2015.242651","article-title":"Clonotypic Light Chain Peptides Identified for Monitoring Minimal Residual Disease in Multiple Myeloma without Bone Marrow Aspiration","volume":"62","author":"Bergen","year":"2016","journal-title":"Clin. Chem."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1021\/pr5000544","article-title":"Monitoring M-proteins in patients with multiple myeloma using heavy-chain variable region clonotypic peptides and LC-MS\/MS","volume":"13","author":"Barnidge","year":"2014","journal-title":"J. Proteome Res."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"S433","DOI":"10.1016\/j.cca.2019.03.920","article-title":"QIP-MS: A specific, sensitive, accurate, and quantitative alternative to electrophoresis that can identify endogenous m-proteins and distinguish them from therapeutic monoclonal antibodies in patients being treated for multiple myeloma","volume":"493","author":"North","year":"2019","journal-title":"Clin. Chim. Acta"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2021.39.15_suppl.8009","article-title":"MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial","volume":"39","author":"Dispenzieri","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"8010","DOI":"10.1200\/JCO.2021.39.15_suppl.8010","article-title":"Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial","volume":"39","author":"Puig","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1182\/blood-2018-99-116604","article-title":"Absence of Contribution to a Differential Outcome of the Stringent Complete Response IMWG Category Respect to the Conventional CR in Multiple Myeloma. A Validation Analysis Based on the Pethema\/GEM2012MENOS65 Phase III Clinical Trial","volume":"132","author":"Rosinol","year":"2018","journal-title":"Blood"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/bjh.16130","article-title":"Challenges and opportunities in the assessment of measurable residual disease in multiple myeloma","volume":"186","author":"Bal","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"4529","DOI":"10.1200\/JCO.2013.49.0086","article-title":"Importance of achieving stringent complete response after autologous stem-cell transplantation in multiple myeloma","volume":"31","author":"Kapoor","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Lopez-Anglada, L., Cueto-Felgueroso, C., Rosi\u00f1ol, L., Oriol, A., Teruel, A.I., Lopez de la Guia, A., Bengoechea, E., Palomera, L., de Arriba, F., and Hernandez, J.M. (2018). Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA\/GEM phase III clinical trials. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0203392"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1182\/blood-2011-07-370460","article-title":"High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma","volume":"119","author":"Paiva","year":"2012","journal-title":"Blood"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2016.69.2517","article-title":"Depth of response in multiple myeloma: A pooled analysis of three PETHEMA\/GEM clinical trials","volume":"35","author":"Lahuerta","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","article-title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: A meta-analysis","volume":"3","author":"Munshi","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1038\/bmt.2016.222","article-title":"Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis","volume":"51","author":"Landgren","year":"2016","journal-title":"Bone Marrow Transplant."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2020006731","article-title":"Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma","volume":"137","author":"Goicoechea","year":"2021","journal-title":"Blood"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1182\/blood-2016-03-705319","article-title":"Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","article-title":"A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma","volume":"4","author":"Munshi","year":"2020","journal-title":"Blood Adv."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00277-019-03609-x","article-title":"Achieving minimal residual disease-negative by multiparameter flow cytometry may ameliorate a poor prognosis in MM patients with high-risk cytogenetics: A retrospective single-center analysis","volume":"98","author":"Li","year":"2019","journal-title":"Ann. Hematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1200\/JCO.2012.46.2119","article-title":"Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: Impact on outcome in the Medical Research Council Myeloma IX study","volume":"31","author":"Rawstron","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2712","DOI":"10.1200\/JCO.2013.54.8164","article-title":"Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: A phase II study by the Intergroupe Francophone du My\u00e9lome","volume":"32","author":"Roussel","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1402888","article-title":"Autologous transplantation and maintenance therapy in multiple myeloma","volume":"371","author":"Palumbo","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1016\/S1470-2045(15)00389-7","article-title":"Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: A randomised, multicentre, phase 3 trial","volume":"16","author":"Gay","year":"2015","journal-title":"Lancet Oncol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"e456","DOI":"10.1016\/S2352-3026(20)30099-5","article-title":"Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02\/HO95): A multicentre, randomised, open-label, phase 3 study","volume":"7","author":"Cavo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.bbmt.2018.12.687","article-title":"Minimal Residual Disease (MRD) Assessment before and after Autologous Hematopoietic Cell Transplantation (AutoHCT) and Maintenance for Multiple Myeloma (MM): Results of the Prognostic Immunophenotyping for Myeloma Response (PRIMeR) Study","volume":"25","author":"Hahn","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.2020010439","article-title":"Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE","volume":"139","author":"Paiva","year":"2022","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1182\/blood.2021012319","article-title":"Validation of the International Myeloma Working Group standard response criteria in the PETHEMA\/GEM2012MENOS65 study: Are these times of change?","volume":"138","author":"Paiva","year":"2021","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.6004\/jnccn.2020.0057","article-title":"Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"18","author":"Kumar","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/joim.12590","article-title":"Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes","volume":"281","author":"Landgren","year":"2017","journal-title":"J. Intern. Med."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1001\/jamaoncol.2021.0611","article-title":"Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial","volume":"7","author":"Landgren","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1016\/j.bbmt.2019.09.015","article-title":"Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling","volume":"26","author":"Holstein","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_133","unstructured":"FDA Guidance for Industry (2022, February 25). Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment, Available online: https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/U."},{"key":"ref_134","unstructured":"(2022, February 25). EMA Guideline on the use of Minimal Residual Disease as a Clinical Endpoint in Multiple Myeloma Studies. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/scienti_cguideline\/%0Adraft-guideline-use-minimal-residual-disease-clinical-endpoint-multiplemyeloma-%0Astudies_en.pdf%0A."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Costa, L.J., Chhabra, S., Medvedova, E., Dholaria, B.R., Schmidt, T.M., Godby, K.N., Silbermann, R., Dhakal, B., Bal, S., and Giri, S. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J. Clin. Oncol., JCO2101935.","DOI":"10.1200\/JCO.21.01935"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1002\/cncr.31854","article-title":"Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysis","volume":"125","author":"Gambella","year":"2019","journal-title":"Cancer"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"4409","DOI":"10.1182\/blood.V128.22.4409.4409","article-title":"Prognostic Impact of Minimal Residual Disease By ASO-RQ-PCR in Multiple Myeloma: A Pooled Analysis of 2 Phase III Studies in Patients Treated with Lenalidomide after Front-Line Therapy","volume":"128","author":"Oliva","year":"2016","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","article-title":"Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): A multicentre, open-label, randomised, phase 3 trial","volume":"20","author":"Jackson","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/bloodadvances.2020001508","article-title":"Prolonged lenalidomide maintenance therapy improves the depth of response in multiple myeloma","volume":"4","author":"Alonso","year":"2020","journal-title":"Blood Adv."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/10428194.2018.1473577","article-title":"Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma","volume":"60","author":"Amsler","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.1002\/cncr.30366","article-title":"Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma","volume":"122","author":"Mian","year":"2016","journal-title":"Cancer"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"2568","DOI":"10.1016\/j.bbmt.2018.07.040","article-title":"Longitudinal Flow Cytometry Identified \u201cMinimal Residual Disease\u201d (MRD) Evolution Patterns for Predicting the Prognosis of Patients with Transplant-Eligible Multiple Myeloma","volume":"24","author":"Gu","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/leu.2014.219","article-title":"Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics\u2019 impact on survival","volume":"29","author":"Ferrero","year":"2015","journal-title":"Leukemia"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"5924","DOI":"10.18632\/oncotarget.12641","article-title":"Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: A prospective analysis","volume":"8","author":"Oliva","year":"2017","journal-title":"Oncotarget"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/s41408-020-0326-1","article-title":"Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed\/refractory multiple myeloma patients: A randomized phase II study","volume":"10","author":"Mina","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1182\/bloodadvances.2021005822","article-title":"Clinical implications of loss of bone marrow minimal residual disease negativity in multiple myeloma","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1182\/blood-2018-99-112571","article-title":"Subgroup Analysis of Patients with Biochemical or Symptomatic Relapse at the Time of Enrollment in the Endeavor Study","volume":"132","author":"Moreau","year":"2018","journal-title":"Blood"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3390\/hemato1020008","article-title":"The Next Step for MRD in Myeloma? Treating MRD Relapse after First Line Treatment in the REMNANT Study","volume":"1","author":"Rasmussen","year":"2020","journal-title":"Hemato"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","article-title":"Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): Results from a randomised, multicentre, open-label, phase 3 study","volume":"396","author":"Dimopoulos","year":"2020","journal-title":"Lancet"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_152","first-page":"1139","article-title":"Evaluation of Sustained Minimal Residual Disease Negativity with Daratumumab-Combination Regimens in Relapsed and\/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR","volume":"39","author":"Casneuf","year":"2021","journal-title":"J. Clin. Med."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"8024","DOI":"10.1200\/JCO.2018.36.15_suppl.8024","article-title":"Early MRD negativity to predict deepening myeloma response in relapsed\/refractory multiple myeloma (RRMM) patients treated with bb2121 anti-BCMA CAR T cells","volume":"36","author":"Munshi","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/blood-2019-122895","article-title":"First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed\/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial","volume":"134","author":"Costa","year":"2019","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","article-title":"Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): A randomised, multicentre, open-label, phase 3 study","volume":"394","author":"Attal","year":"2019","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1038\/s41375-020-0711-6","article-title":"Daratumumab plus lenalidomide and dexamethasone in relapsed\/refractory multiple myeloma: Extended follow-up of POLLUX, a randomized, open-label, phase 3 study","volume":"34","author":"Bahlis","year":"2020","journal-title":"Leukemia"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1182\/blood-2021-146060","article-title":"Updated Results from CARTITUDE-1: Phase 1b\/2Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Patients With Relapsed\/Refractory Multiple Myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2019-124953","article-title":"Long-Term Follow-up of a Phase 1, First-in-Human Open-Label Study of LCAR-B38M, a Structurally Differentiated Chimeric Antigen Receptor T (CAR-T) Cell Therapy Targeting B-Cell Maturation Antigen (BCMA), in Patients (pts) with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"134","author":"Wang","year":"2019","journal-title":"Blood"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Dietrich","year":"2021","journal-title":"Nat. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"8504","DOI":"10.1200\/JCO.2020.38.15_suppl.8504","article-title":"Orvacabtagene autoleucel (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed\/refractory multiple myeloma (RRMM): Update of the phase 1\/2 EVOLVE study (NCT03430011)","volume":"38","author":"Mailankody","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1182\/bloodadvances.2020004017","article-title":"Chimeric antigen receptor T-cell therapy in multiple myeloma: A systematic review and meta-analysis of 950 patients","volume":"5","author":"Mohyuddin","year":"2021","journal-title":"Blood Adv."},{"key":"ref_163","doi-asserted-by":"crossref","unstructured":"Bravo-P\u00e9rez, C., Sola, M., Teruel-Montoya, R., Garc\u00eda-Malo, M.D., Ortu\u00f1o, F.J., Vicente, V., de Arriba, F., and Jerez, A. (2021). Minimal Residual Disease in Multiple Myeloma: Something Old, Something New. Cancers, 13.","DOI":"10.3390\/cancers13174332"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/JCO.2020.38.15_suppl.8511","article-title":"Updated analysis of a phase I\/II study of venetoclax in combination with daratumumab and dexamethasone, +\/- bortezomib, in patients with relapsed\/refractory multiple myeloma","volume":"38","author":"Kaufman","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-142298","article-title":"The Bone Marrow Microenvironment of Multiple Myeloma Long-Term Survivors at Single Cell Resolution","volume":"136","author":"Lutz","year":"2020","journal-title":"Blood"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2017005447","article-title":"Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT","volume":"1","author":"Ho","year":"2017","journal-title":"Blood Adv."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.bbmt.2018.11.015","article-title":"Peripheral Immunotype Correlates with Minimal Residual Disease Status and Is Modulated by Immunomodulatory Drugs in Multiple Myeloma","volume":"25","author":"Bhutani","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Papadimitriou, K., Tsakirakis, N., Malandrakis, P., Vitsos, P., Metousis, A., Orologas-Stavrou, N., Ntanasis-Stathopoulos, I., Kanellias, N., Eleutherakis-Papaiakovou, E., and Pothos, P. (2020). Deep Phenotyping Reveals Distinct Immune Signatures Correlating with Prognostication, Treatment Responses, and MRD Status in Multiple Myeloma. Cancers, 12.","DOI":"10.3390\/cancers12113245"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1038\/leu.2013.166","article-title":"A multiparameter flow cytometry immunophenotypic algorithm for the identification of newly diagnosed symptomatic myeloma with an MGUS-like signature and long-term disease control","volume":"27","author":"Paiva","year":"2013","journal-title":"Leukemia"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3324\/haematol.2012.067272","article-title":"Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry","volume":"98","author":"Vidriales","year":"2013","journal-title":"Haematologica"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/blood-2021-154506","article-title":"Normalization of the Immune Microenvironment during Lenalidomide Maintenance Is Associated with Sustained MRD Negativity in Patients with Multiple Myeloma","volume":"138","author":"Coffey","year":"2021","journal-title":"Blood"},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","article-title":"A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1","volume":"109","author":"Shaughnessy","year":"2007","journal-title":"Blood"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1182\/blood-2006-07-037077","article-title":"Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis","volume":"109","author":"Zhan","year":"2007","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"e313","DOI":"10.3324\/haematol.2017.165217","article-title":"The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype","volume":"102","author":"Schinke","year":"2017","journal-title":"Haematologica"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.6004\/jnccn.2021.0042","article-title":"Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Brown","year":"2021","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref_179","unstructured":"(2022, February 25). Clinicaltrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/home."}],"container-title":["Hemato"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2673-6357\/3\/3\/27\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:38:36Z","timestamp":1760139516000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2673-6357\/3\/3\/27"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,23]]},"references-count":179,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,9]]}},"alternative-id":["hemato3030027"],"URL":"https:\/\/doi.org\/10.3390\/hemato3030027","relation":{},"ISSN":["2673-6357"],"issn-type":[{"type":"electronic","value":"2673-6357"}],"subject":[],"published":{"date-parts":[[2022,6,23]]}}}